Issue #1

MYELOMA CLINICAL TRIALS
Data Driven Individualized Treatments for every patient – Pathway towards cure

MCT-Myeloma Clinical Trials LLC
445 Park Avenue, 9th Floor New York, NY, 10022 Tel: 1-212-634-7914

Mission Statement
To provide a seamless source of information for patients and caregivers all around the world to learn more about Multiple Myeloma and treatment options available including enrollment in Clinical trials.

To provide answers to frequently asked questions that arise during this journey and to empower patients and family members with knowledge through trusted sources in their fight against cancer.

To provide a useful resource for community oncologists involved in treating Myeloma patients to formulate Data Driven Individualized Treatment plans for patients, aiming for longer remissions, and turning remissions into cure.

To work in collaboration with Myeloma community organizations towards one common goal: CURE MYELOMA

After 5 years of treating Myeloma Patients at Mount Sinai NYC, Afshin Malik, MD, Myeloma Oncologist from New York City created MCT, a free global education platform for the myeloma community.

MCT Multiple Myeloma Clinical Trials (themyelomaclinicaltrials.com) was established in late 2021 with a goal of creating the most comprehensive database for myeloma clinical trials, to deliver accurate and current information on all myeloma clinical trials.

MCT’s database is growing since its launch, now including over 400 Myeloma Clinical Trials. MCT appears in search results for top Myeloma trials in all search engines like Google and Bing. 1300 unique visitors explored MCT in August 2022.

MCT is rapidly growing popularity in Multiple Myeloma Community, due to the wealth of information in easy to search format.

MCT provides a great resource tool for Myeloma community, patients, and caregivers as well as residents/fellows and community oncologists to research Multiple Myeloma Clinical trials.

Increased clinical trial education will result in a greater number of myeloma patients enrolling in clinical trials. Together, as the Myeloma Community, this will help us find cure for myeloma.

Newly Diagnosed MM
146 Clinical Trials
NDMM Trials | Myeloma Trials (themyelomaclinicaltrials.com)

Relapsed & Refractory MM
295 Clinical Trials
RRMM Trials | Myeloma Trials (themyelomaclinicaltrials.com)

MGUS & Smoldering MM
34 Clinical Trials
MGUS/SMM Trials | Myeloma Trials (themyelomaclinicaltrials.com)

The passion to pursue excellence in treatment of Multiple Myeloma.
MCT’s Most popular posts - August 2022
Visitor’s top picks

19th International Myeloma Society Annual Meeting; Aug 25-27, LA California #IMS2022

NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM - (No ASCT planned) CARTITUDE-5

NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVD in Relapsed or Refractory Myeloma MajesTEC-3

What are Multiple myeloma defining events? International Myeloma Working Group - SLiM-CRAB Criteria

NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT MajesTEC-4

NCT03652064 : Phase 3 - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM MMY3019 CEPHEUS

NCT01208662 - Phase 3 - Delayed vs Early Transplant with RVd & Revlimid Maint. DETERMINATION Trial

NCT04923893: Phase 3 - VRd followed by Cilta-cel Vs VRd f/b Rd - NDMM - (No ASCT planned) CARTITUDE-5

NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVD in Relapsed or Refractory Myeloma MajesTEC-3

NCT03715478: Phase 1/2: Multi-Center Study of GSK2857916 With Pomalidomide & Dex Algonquin trial

NCT083715478: Phase 1/2: Multi-Center Study of GSK2857916 With Pomalidomide & Dex Algonquin trial

NCT05020236: Phase 3: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex MagnetisMM-5
MCT’s Most popular posts - August 2022

Visitor’s top picks

NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies
TRIMM-2

NCT02874742: Phase 2 - Daratumumab, Len., Bortezomib & Dex (D-RVd) Vs (RVd) in New MM
GRIFFIN

NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma
DETER-SMM

Featured Trials

MGUS/SMM

NCT04920084: A Study of a Plant-Based Diet in People With MGUS / Smoldering Myeloma
NUTRIVENTION

NCT03689595: Predicting Progression of Developing MM in a High-Risk Screened Population
PROMISE

The PCROWD Study invites people with precursor conditions to Share samples a few times each year

NCT04934475: Phase 3 - IFM 2020-02 Minimal Residual Disease Adapted Strategy KRD-Isatuximab
MIDAS

NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM
(Perseus) EMN17

NCT04855136: Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM
KarMMa-7

NCT08761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
LINKER-MM1
MCT Traffic Sources – August 2022

- **0.8%** Website Referrals (17 visits)
- **5%** Social Traffic (194 visits)
- **17.3%** Direct Traffic (301 visits)
- **76.7%** Search Traffic (1,956 visits)

Featured Myeloma Centers

- **MAYO CLINIC**
  - TNB-383B
  - BCMA x CD3 BITE

- **DANA FARBER**
  - PHE885
  - Allogeneic BCMA-specific CAR T cells

- **MOUNT SINAI NY**
  - D - vRd

Featured Myeloma Conferences 2022

- **#ASCO22**
- **#EHA2022**
- **#COMY22**
- **#IMS2022**

Join us in creating the most comprehensive platform for Myeloma Clinical Trials

contact@mmeducation.org